8-K: Verastem Reports Strong 2025 Revenue, Extends Cash Runway

Verastem Oncology announced preliminary Q4 and full-year 2025 net product revenues for AVMAPKI FAKZYNJA CO-PACK, along with an extended cash runway into the first half of 2027 and key 2026 strategic priorities.

Summary

• Reported preliminary, unaudited AVMAPKI FAKZYNJA CO-PACK net product revenues of approximately $17.5 million for Q4 2025 and $30.9 million for the full year 2025.
• The full year 2025 revenue reflects the launch period from May 2025, following U.S. FDA approval, through December 2025.
• Preliminary unaudited cash, cash equivalents, and investments stood at $205 million as of December 31, 2025.
• Pro-forma cash, cash equivalents, and investments were $234 million, inclusive of $29.4 million net proceeds from the exercise of expiring cash warrants as of January 25, 2026.
• Expects cash runway to extend into the first half of 2027.
• Anticipates the LGSOC commercial launch and development program for AVMAPKI FAKZYNJA CO-PACK to be self-sustaining by the second half of 2026.
• Provided updated data from the RAMP201J Phase 2 clinical trial in Japan for AVMAPKI FAKZYNJA CO-PACK in LGSOC, showing a confirmed overall response rate (ORR) of 38% (6/16) in efficacy evaluable patients.
• In KRAS-mutated recurrent LGSOC patients, the confirmed ORR was 57% (4/7) and disease control rate (DCR) was 100% (7/7).
• In KRAS wild-type recurrent LGSOC patients, the confirmed ORR was 22% (2/9) and DCR was 89% (8/9).
• Continued enrollment in the international Phase 1/2 trial for VS-7375, a KRAS G12D inhibitor, in advanced solid tumors, with no dose-limiting toxicities (DLTs) reported at 400, 600, and 900 mg once daily (QD) monotherapy doses.
• Reported an 83% (10/12) ORR for the first 12 patients in the RAMP 205 study evaluating avutometinib plus defactinib with standard-of-care chemotherapy in front-line metastatic PDAC.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive update, reflecting strong commercial execution for AVMAPKI FAKZYNJA CO-PACK, a significantly extended cash runway, and promising clinical progress for its pipeline assets, particularly VS-7375.

Positives

• Achieved approximately $30.9 million in net product revenues for AVMAPKI FAKZYNJA CO-PACK in its first eight months post-FDA approval.
• Extended cash runway into the first half of 2027, providing financial stability.
• Anticipates the AVMAPKI FAKZYNJA CO-PACK program to be self-sustaining by H2 2026.
• Positive interim data from the RAMP201J Phase 2 trial in Japan for AVMAPKI FAKZYNJA CO-PACK, particularly a 57% ORR and 100% DCR in KRAS-mutated LGSOC patients.
• VS-7375, a potential best-in-class KRAS G12D inhibitor, continues to advance in clinical trials with no dose-limiting toxicities reported at high doses.
• Strong 83% ORR reported in the RAMP 205 study for pancreatic cancer, indicating promising efficacy for the combination therapy.

Risks

• Uncertainties inherent in research and development, including the possibility of negative or unexpected results of clinical trials.
• Potential for not seeing a return on investment from the collaboration and option agreement with GenFleet, or GenFleet failing to perform.
• Challenges in the continued launch and commercialization of AVMAPKI FAKZYNJA CO-PACK.
• Development and commercialization of product candidates may take longer or cost more than planned.
• Data may not be available when expected, and preliminary/interim data may not be representative of more mature data.
• Risks associated with recent changes in administration policy or actions that may create regulatory uncertainty.
• Risks associated with reductions to the FDA's workforce, potentially leading to disruptions and delays in review and oversight.
• Product candidates may not receive regulatory approval, become commercially successful, or result in new treatment options.

Future Outlook

Verastem expects its cash runway to extend into the first half of 2027 and anticipates the AVMAPKI FAKZYNJA CO-PACK commercial launch and development program to be self-sustaining by the second half of 2026. The company plans to maximize adoption of AVMAPKI FAKZYNJA CO-PACK in the U.S., report topline data from the RAMP 301 trial in mid-2027, and pursue regulatory paths for expansion into Europe and Japan. For VS-7375, an interim update on the Phase 1/2 trial is expected in 1H 2026, with plans to engage the FDA for potential registration-directed trials in PDAC, NSCLC, and CRC. An update on the RAMP 205 expansion cohort is expected in Q2 2026.

Management Comments

• "2025 was a transformative year for Verastem Oncology and the patients we serve. We transitioned to a commercial-stage company with the launch of AVMAPKI FAKZYNJA CO-PACK, the first treatment specifically approved by the FDA for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC)."
• "We also advanced multiple clinical programs across several RAS/MAPK pathway-driven solid tumor cancers."
• "In 2026, we are well-positioned to drive sustainable growth with our successful commercial launch and to accelerate our clinical path for VS-7375, our potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, with several important data readouts and preparations for potential registration-directed clinical trials."

Industry Context

StockSavvy.ai notes that Verastem's successful commercial launch of AVMAPKI FAKZYNJA CO-PACK for a specific, underserved indication (KRAS-mutated LGSOC) positions it favorably in the competitive oncology market. The continued advancement of its pipeline, particularly the KRAS G12D inhibitor VS-7375, aligns with the industry's focus on precision oncology and targeting difficult-to-treat mutations. The strong preliminary revenue figures and extended cash runway suggest effective market penetration and financial prudence, which are critical for biopharmaceutical companies in the commercialization phase.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Positive impact due to strong preliminary revenue, extended cash runway, and promising pipeline progress, potentially leading to increased shareholder value.
• Patients: Continued development and commercialization of therapies for RAS/MAPK pathway-driven cancers, offering new treatment options, especially for KRAS-mutated LGSOC and other solid tumors.
• Employees: Stable outlook due to financial health and ongoing clinical development, supporting job security and growth opportunities.
• Regulatory Authorities: Ongoing engagement with FDA for development paths and confirmatory trials, ensuring compliance and continued oversight.

Next Steps

• Maximize adoption of AVMAPKI FAKZYNJA CO-PACK in the U.S. as the treatment of choice at the earliest recurrence.
• Report a topline readout of the primary endpoint in the RAMP 301 trial in mid-2027.
• Continue to pursue regulatory paths for potential expansion of AVMAPKI FAKZYNJA CO-PACK launch into Europe and Japan.
• Report an interim update on the Phase 1/2 trial of VS-7375 in 1H 2026.
• Select the recommended Phase 2 dose (RP2D) for VS-7375 with cetuximab and initiate the CRC combination expansion cohort in 1H 2026.
• Engage with the FDA in 1H 2026 to discuss the development path forward for VS-7375, including potential registration-directed clinical trials in PDAC, NSCLC, and CRC.
• Complete enrollment in VS-7375 combination dose-escalation cohorts in mid-2026.
• Complete enrollment in VS-7375 monotherapy expansion cohorts in 2H 2026.
• Select the RP2D for VS-7375 and plan to initiate the PDAC and NSCLC combination expansion cohorts in 2H 2026.
• Report an update on the safety and efficacy of the RAMP 205 expansion cohort with at least six months of follow-up on all patients in Q2 2026.
• Leadership to participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026.
• Report final Q4 2025 and full year 2025 results during its fourth quarter 2025 earnings call in early March 2026.

Key Dates

Recommendation

The filing presents a highly positive outlook for Verastem Oncology. The preliminary 2025 revenues for AVMAPKI FAKZYNJA CO-PACK demonstrate a successful commercial launch and strong market acceptance for its first FDA-approved product. The extension of the cash runway into the first half of 2027, bolstered by warrant exercises, significantly de-risks the company's financial position and provides ample capital for continued pipeline development. The promising clinical data for VS-7375, a potential best-in-class KRAS G12D inhibitor, and the positive results from the RAMP 205 study for pancreatic cancer, indicate a robust and advancing pipeline. The anticipation of the LGSOC program becoming self-sustaining by H2 2026 further underscores operational efficiency and future profitability. These factors collectively suggest strong growth potential and a favorable investment opportunity.

Keywords

Verastem Oncology, VSTM, AVMAPKI FAKZYNJA CO-PACK, avutometinib, defactinib, KRAS G12D inhibitor, VS-7375, RAS/MAPK pathway, low-grade serous ovarian cancer, LGSOC, pancreatic ductal adenocarcinoma, PDAC, non-small cell lung cancer, NSCLC, colorectal cancer, CRC, biopharmaceutical, oncology, clinical trials, FDA approval, financial results, cash runway